Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01508312
Recruitment Status : Active, not recruiting
First Posted : January 11, 2012
Last Update Posted : December 2, 2017
Seattle Genetics, Inc.
Hôpitaux Universitaires Henri Mondor, France
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center